Get startedLog in
    Picture of Hikma Pharmaceuticals logo

    HIK — Hikma Pharmaceuticals Cashflow Statement

    0.000.00%
    gb flag iconLast trade - 00:00
    HealthcareBalancedLarge CapNeutral
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Hikma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line558544233281455
    Depreciation
    Amortisation
    Non-Cash Items84108112117201
    Unusual Items
    Equity in Net Earnings/Losses
    Other Non-Cash Items
    Changes in Working Capital-269-159-187-49-260
    Change in Accounts Receivable
    Change in Inventories
    Change in Other Assets
    Change in Payable / Accrued Expenses
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities464638530608564
    Capital Expenditures-224-229-225-204-235
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items-59-9-382-129-146
    Acquisition of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Sale of Intangible Assets
    Other Investing Cash Flow
    Cash from Investing Activities-283-238-607-333-381
    Financing Cash Flow Items-34-53-77-97-78
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Stock
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-298-287-58-337-188
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash-119103-156-65-17